Abstract:
The present invention is directed to methods and devices for amending undiluted and partially diluted urine samples in a manner suitable for performing immunoassays for target analytes, for example NGAL. Generally, the urine sample is treated with reagents including at least one of buffer materials, water soluble proteins, urease, and other interferent mitigants. These reagents control the pH of the urine sample in a manner suitable for immuno-binding reactions and ameliorate interferences, particularly during the detection step.
Abstract:
Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample.
Abstract:
A synthetic urine solution and method of its manufacture are disclosed. The solution includes water having a pH between about 3 and about 10. The solution further includes creatinine, a means for removing bacteria from the solution so as to control or eliminate sepsis of the urine solution, preferably through the use of a biocide, and a urea-based compound. The solution exhibits a specific gravity of from 1.005 g/cm3 to 1.025 g/cm3. Additional compounds may also be included to further enhance the aesthetics or apparent authenticity of the synthetic urine.
Abstract translation:公开了一种合成尿液及其制造方法。 溶液包括pH在约3和约10之间的水。该溶液还包括肌酸酐,用于从溶液中除去细菌以控制或消除尿液溶液的败血症的方法,优选通过使用杀生物剂,以及 脲基化合物。 溶液的比重为1.005g / cm 3至1.025g / cm 3。 还可以包括另外的化合物以进一步增强合成尿的美观性或表观真实性。
Abstract:
The present invention pertains to the field of diagnostics for kidney toxicity and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing kidney toxicity. It also relates to a method for determining whether a compound is capable of inducing such kidney toxicity in a subject and to a method of identifying a drug for treating kidney toxicity. Furthermore, the present invention relates to a device and a kit for diagnosing kidney toxicity.
Abstract:
A synthetic urine solution and method of its manufacture are disclosed. The solution includes water having a pH between about 3 and about 10. The solution further includes creatinine, a means for removing bacteria from the solution so as to control or eliminate sepsis of the urine solution, preferably through the use of a biocide, and a urea-based compound. The solution exhibits a specific gravity of from 1.005 g/cm3 to 1.025 g/cm3. Additional compounds may also be included to further enhance the aesthetics or apparent authenticity of the synthetic urine.
Abstract translation:公开了一种合成尿液及其制造方法。 溶液包括pH在约3和约10之间的水。该溶液还包括肌酸酐,用于从溶液中除去细菌以控制或消除尿液溶液的败血症的方法,优选通过使用杀生物剂,以及 脲基化合物。 溶液的比重为1.005g / cm 3至1.025g / cm 3。 还可以包括另外的化合物以进一步增强合成尿的美观性或表观真实性。
Abstract:
This invention relates to a novel comprehensive composition comprising the major inorganic salts, urea, organic compounds, organic ammonium salts, proteins and human immuglobins present in normal human urine formulated into unisex synthetic human urine.
Abstract:
A skin treatment regimen for delivery of a rinse-off personal skin care composition is provided. The rinse-off personal skin care composition includes varying ratios of a lathering agent to a hydrophobic benefit agent. The rinse-off personal skin care composition can be applied to skin of a user in phases over and/or in a treatment cycle. Each of the phases of the treatment cycle can include a ratio of the varying ratios that can be different such as higher or lower than a ratio of adjacent phase.
Abstract:
A skin treatment regimen for delivery of a rinse-off personal skin care composition is provided. The rinse-off personal skin care composition includes varying ratios of a lathering agent to a hydrophobic benefit agent. The rinse-off personal skin care composition can be applied to skin of a user in phases over and/or in a treatment cycle. Each of the phases of the treatment cycle can include a ratio of the varying ratios that can be different such as higher or lower than a ratio of adjacent phase.
Abstract:
A skin treatment regimen for delivery of a rinse-off personal skin care composition is provided. The rinse-off personal skin care composition includes varying ratios of a lathering agent to a hydrophobic benefit agent. The rinse-off personal skin care composition can be applied to skin of a user in phases over and/or in a treatment cycle. Each of the phases of the treatment cycle can include a ratio of the varying ratios that can be different such as higher or lower than a ratio of adjacent phase.
Abstract:
Provided herein are methods for identifying and characterizing agents that alter the volume of a cell. Methods are provided for rapid screening and identification of an agent that alters the capability of a small, neutrally charged solute transporter to transport the solute across a cell membrane. The methods described herein may be used to identify and characterize inhibitors of urea transporters, to identify and characterize inhibitors of aquaporins, and to identify and characterize inhibitors of other small, neutrally charged solutes such as glucose.